AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dyne Therapeutics, Inc. Director's Dealing 2021

Jul 15, 2021

31790_dirs_2021-07-15_eeaaee27-6b95-4cc0-ae88-52bcafecece1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Dyne Therapeutics, Inc. (DYN)
CIK: 0001818794
Period of Report: 2021-07-13

Reporting Person: Atlas Venture Fund XI, L.P. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-13	Common Stock	J	814013	$0.00	Disposed	7326117	Direct

Footnotes

F1: Represents a pro rata distribution, and not a purchase or sale of securities, by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI") to its general
partner and limited partners without additional consideration. This distribution was effected pursuant to a plan adopted by Atlas Venture Fund XI
pursuant to Rule 10b5-1 on June 11, 2021.